BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 20675072)

  • 1. 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients.
    Crook J; Borg J; Evans A; Toi A; Saibishkumar EP; Fung S; Ma C
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1323-9. PubMed ID: 20675072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iodine-125 Brachytherapy for Palliative Treatment of Painful Colorectal Cancer Port-Site Metastases.
    Liu X; Yu H; Zhao J; Di X; Wang J; Zhang H
    J Gastrointest Cancer; 2024 Mar; 55(1):198-201. PubMed ID: 37889435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-Specific Antigen Bounce after
    Kim TH; Lee JJB; Cho J
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up.
    Behmueller M; Tselis N; Zamboglou N; Zoga E; Baltas D; Rödel C; Chatzikonstantinou G
    Front Oncol; 2021; 11():770959. PubMed ID: 34926278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of outcomes after non-contour-based dose painting of dominant intra-epithelial lesion in intra-operative low-dose rate brachytherapy.
    Martell K; Roy S; Meyer T; Stosky J; Jiang W; Thind K; Roumeliotis M; Bosch J; Angyalfi S; Quon H; Husain S
    Heliyon; 2020 Jun; 6(6):e04092. PubMed ID: 32548323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate.
    Fischer-Valuck BW; Gay HA; Patel S; Baumann BC; Michalski JM
    Front Oncol; 2019; 9():1378. PubMed ID: 31921640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
    Matzkin H; Chen J; Agai R; Ziv-Baran T; Mabjeesh NJ
    PLoS One; 2019; 14(4):e0215582. PubMed ID: 31002732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose rate prostate brachytherapy.
    Stish BJ; Davis BJ; Mynderse LA; McLaren RH; Deufel CL; Choo R
    Transl Androl Urol; 2018 Jun; 7(3):341-356. PubMed ID: 30050795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COMP report: CPQR technical quality control guidelines for low-dose-rate permanent seed brachytherapy.
    Beaulieu L; Radford DA; Eduardo Villarreal-Barajas J
    J Appl Clin Med Phys; 2018 May; 19(3):13-18. PubMed ID: 29542269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of 125I brachytherapy with and without external-beam radiation therapy for localized prostate cancer: results from 300 patients at a single institution in Japan.
    Maki S; Itoh Y; Kubota S; Okada T; Nakahara R; Ito J; Kawamura M; Naganawa S; Yoshino Y; Fujita T; Kato M; Gotoh M; Ikeda M
    J Radiat Res; 2017 Nov; 58(6):870-880. PubMed ID: 28992050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected Seed Migration in Prostate Brachytherapy Implants Coincident with Change in Seed Stranding Product.
    Rose J; Liu D; Boychak O; Sloboda R; Pervez N; Murtha A; Yee D; Amanie J; Usmani N
    Cureus; 2017 May; 9(5):e1243. PubMed ID: 28620572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Gleason Pattern 5 on outcomes of patients with prostate cancer and iodine-125 prostate brachytherapy.
    Makino T; Miwa S; Koshida K
    Prostate Int; 2016 Dec; 4(4):152-155. PubMed ID: 27995115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen nadir concentration, hypertension and diabetes as risk factors for biochemical failure after permanent
    Kovalainen E; Vaarala MH
    Mol Clin Oncol; 2016 Nov; 5(5):647-650. PubMed ID: 27900104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.
    Fellin G; Mirri MA; Santoro L; Jereczek-Fossa BA; Divan C; Mussari S; Ziglio F; La Face B; Barbera F; Buglione M; Bandera L; Ghedi B; Di Muzio NG; Losa A; Mangili P; Nava L; Chiarlone R; Ciscognetti N; Gastaldi E; Cattani F; Spoto R; Vavassori A; Giglioli FR; Guarneri A; Cerboneschi V; Mignogna M; Paoluzzi M; Ravaglia V; Chiumento C; Clemente S; Fusco V; Santini R; Stefanacci M; Mangiacotti FP; Martini M; Palloni T; Schinaia G; Lazzari G; Silvano G; Magrini S; Ricardi U; Santoni R; Orecchia R
    Br J Radiol; 2016 Sep; 89(1065):20150981. PubMed ID: 27384381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemiablative Focal Low Dose Rate Brachytherapy: A Phase II Trial Protocol.
    Fernandez Ots A; Bucci J; Chin YS; Malouf D; Howie A; Enari KE
    JMIR Res Protoc; 2016 Jun; 5(2):e98. PubMed ID: 27296781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of permanent (125)I seeds implants with two different techniques in 500 cases of prostate cancer.
    Guinot JL; Ricós JV; Tortajada MI; Santos MA; Casanova J; Clemente J; Samper J; Santamaría P; Arribas L
    J Contemp Brachytherapy; 2015 Aug; 7(4):258-64. PubMed ID: 26622228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the dosimetric impact of loss and displacement of seeds in prostate low-dose-rate brachytherapy.
    Wang Y; Nasser NJ; Borg J; Saibishkumar EP
    J Contemp Brachytherapy; 2015 Jun; 7(3):203-10. PubMed ID: 26207108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo visualization of prostate brachytherapy seeds with photoacoustic imaging.
    Lediju Bell MA; Kuo NP; Song DY; Kang JU; Boctor EM
    J Biomed Opt; 2014 Dec; 19(12):126011. PubMed ID: 25531797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil.
    Pugh TJ; Mahmood U; Swanson DA; Munsell MF; Wang R; Kudchadker RJ; Bruno TL; Frank SJ
    Brachytherapy; 2015; 14(2):160-5. PubMed ID: 25255712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.
    Arscott WT; Chen LN; Wilson N; Bhagat A; Kim JS; Moures RA; Yung TM; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Jul; 9():163. PubMed ID: 25056726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.